litlas
Log inCreate account

Mark A. Socinski

Active 1984–2025

Also published as
Mark A Socinski
126
Papers
30,338
Citations
85
h-index
124
i10-index

Citations

Citations per year for Mark A. Socinski1983: 1 citations1989: 13 citations1990: 17 citations1991: 13 citations1992: 16 citations1993: 12 citations1994: 5 citations1995: 9 citations1996: 1 citations1997: 2 citations1998: 3 citations1999: 4 citations2000: 1 citations2001: 3 citations2002: 6 citations2003: 24 citations2004: 18 citations2005: 31 citations2006: 32 citations2007: 70 citations2008: 91 citations2009: 117 citations2010: 136 citations2011: 149 citations2012: 131 citations2013: 180 citations2014: 150 citations2015: 220 citations2016: 217 citations2017: 273 citations2018: 392 citations2019: 1,288 citations2020: 1,517 citations2021: 1,363 citations2022: 1,118 citations2023: 837 citations2024: 1,252 citations2025: 549 citations2026: 6 citations1984–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,276 citing papers, 23.8% of this breakdownChina: 2,081 citing papers, 15.1% of this breakdownItaly: 739 citing papers, 5.4% of this breakdownJapan: 729 citing papers, 5.3% of this breakdownUnited Kingdom: 650 citing papers, 4.7% of this breakdownFrance: 644 citing papers, 4.7% of this breakdownGermany: 601 citing papers, 4.4% of this breakdownSpain: 512 citing papers, 3.7% of this breakdownCanada: 416 citing papers, 3% of this breakdownSouth Korea: 354 citing papers, 2.6% of this breakdownNetherlands: 347 citing papers, 2.5% of this breakdownSwitzerland: 331 citing papers, 2.4% of this breakdown
0%23.8%Other 22.4%

Institutions

Fields

  • Medicine76.8%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology3.4%
  • Materials Science1.2%
  • Engineering0.9%
  • Computer Science0.8%
  • Other2%

Topics

  • Lung Cancer Treatments and Mutations13.8%
  • Cancer Immunotherapy and Biomarkers12.9%
  • Lung Cancer Research Studies8%
  • Lung Cancer Diagnosis and Treatment5.8%
  • Cancer Genomics and Diagnostics4%
  • Immunotherapy and Immune Responses2.9%
  • Other52.6%

Coauthors

All papers

Open in search
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 cited by 3,753

  2. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    Authors: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 cited by 2,575

  3. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark L. McCleland, Geetha Shankar, Martin Reck - Journal of Thoracic Oncology 2021 cited by 523

  4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    Authors: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 cited by 939

  5. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

    Authors: Makoto Nishio, Fabrice Barlési, Howard West, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, G. Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski - Journal of Thoracic Oncology 2020 cited by 458

  6. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  7. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

    Authors: Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony Mok, Gene Grant Finley, Joachim G.J.V. Aerts, Francesco Orlandi, Denis Moro‐Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodríguez‐Abreu, Wan‐Teck Lim, David M. Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bāra, Makoto Nishio - Journal of Thoracic Oncology 2021 cited by 303

  8. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Authors: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 cited by 607

  9. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony Mok, Martin Reck, Gene Grant Finley, Monika Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard West - JAMA Oncology 2023 cited by 186

  10. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    Authors: Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze - Nature Medicine 2023 cited by 139

  11. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    Authors: Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski - Nature Medicine 2022 cited by 170

  12. Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

    Authors: Xiuning Le, Robin Cornelissen, Marina Chiara Garassino, Jeffrey Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, François Lebel, John V. Heymach, Mark A. Socinski - Journal of Clinical Oncology 2021 cited by 154

  13. Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

    Authors: Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. VanderWalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes, Alexander I. Spira, W. Michael Korn, Edward S. Kim, Stephen V. Liu, Hossein Borghaei - Molecular Cancer Therapeutics 2021 cited by 186

  14. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    Authors: Howard West, Mark L. McCleland, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David S. Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski - Journal for ImmunoTherapy of Cancer 2022 cited by 151

  15. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Authors: Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor–Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd - The Lancet Oncology 2013 cited by 526

  16. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    Authors: David Planchard, Tae Min Kim, Julien Mazières, Élisabeth Quoix, Gregory J. Riely, Fabrice Barlési, Pierre‐Jean Souquet, Egbert F. Smit, Harry J.M. Groen, Ronan J. Kelly, Byoung Chul Cho, Mark A. Socinski, Lini Pandite, Christine Nase, Bo Ma, Anthony M. D’Amelio, Bijoyesh Mookerjee, C. Martin Curtis, Bruce E. Johnson - The Lancet Oncology 2016 cited by 444

  17. Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

    Authors: Kyle Wang, Michael J. Eblan, Allison M. Deal, Matthew B. Lipner, Timothy M. Zagar, Yue Wang, Panayiotis Mavroidis, Carrie B. Lee, Brian C. Jensen, Julian Rosenman, Mark A. Socinski, Thomas E. Stinchcombe, Lawrence B. Marks - Journal of Clinical Oncology 2017 cited by 427

  18. Crizotinib in Patients With MET-Amplified NSCLC

    Authors: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 cited by 168

  19. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Authors: Mark A. Socinski, Igor Bondarenko, Nina Karaseva, Anatoly Makhson, Igor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, Hui Zhang, J. L. Mesías Iglesias, Markus F. Renschler - Journal of Clinical Oncology 2012 cited by 754

  20. Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

    Authors: Joachim von Pawel, Robert M. Jotte, David R. Spigel, Mary O’Brien, Mark A. Socinski, J. Mezger, Martin Steins, Leon Bosquée, Jeffrey A. Bubis, Kristiaan Nackaerts, José Trigo, Philip Clingan, Wolfgang Schütte, Paul Lorigan, Martin Reck, Manuel Dómine, Frances A. Shepherd, Shaoyi Li, Markus F. Renschler - Journal of Clinical Oncology 2014 cited by 344

  21. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Authors: Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher - Journal of Thoracic Oncology 2017 cited by 243

  22. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

    Authors: Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina S. Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina Chiara Garassino, John V. Heymach, Mark A. Socinski, Szu‐Yun Leu, Gajanan Bhat, François Lebel, Xiuning Le - Journal of Thoracic Oncology 2023 cited by 55

  23. Clinicopathologic Features of Advanced Squamous NSCLC

    Authors: Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher - Journal of Thoracic Oncology 2016 cited by 197

  24. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

    Authors: Bruna Pellini, Russell W. Madison, Merrida Childress, Shoshana T. Miller, Ole Gjoerup, Jason Cheng, Richard S.P. Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich, M. Ballinger, Minetta C. Liu, Amanda Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski - Clinical Cancer Research 2023 cited by 45